Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Alumis reported additional Phase 3 ONWARD data for investigational envudeucitinib, including 54% PASI 100 skin clearance at Week 48, more than 80% clear or almost-clear scalp skin, and nearly 80% sustained clinically meaningful itch reduction through Week 48. The company said switching patients achieved improvements comparable to continuous treatment and reported no new long-term safety signals. Alumis remains on track to submit an NDA for moderate-to-severe plaque psoriasis in 4Q 2026; regulatory approval is not yet assured.

Analysis

The commercial read-through is more important than the incremental symptom data: if the efficacy profile survives review and translates into prescribing, envudeucitinib could pressure oral incumbents such as Bristol Myers Squibb’s Sotyktu and Amgen’s Otezla, while taking share from injectable biologics among patients who prioritize oral dosing. That is a segment-share thesis, not evidence that biologics such as AbbVie’s Skyrizi will lose broad market share; payer access, net price, and physician comfort will govern uptake.

The key evidentiary discount is that the long-term extension is open-label, and crossover patients no longer provide a durable randomized comparison. The 48-week response narrative therefore supports persistence but does not establish comparative superiority or real-world adherence. “Highest publicly reported” is also a cross-trial comparison, not a head-to-head result. Safety differentiation and FDA review of the full dataset matter at least as much as peak efficacy.

Near term, the 4Q26 filing is the clearest catalyst; acceptance and review milestones then replace trial headlines as the value drivers. Over 6–18 months, launch execution, payer positioning, and refill persistence determine whether the asset earns a premium commercial multiple. The contrarian risk is that investors capitalize a best-in-class label before resolving launch economics and funding needs. Verify cash runway, launch costs, proposed pricing, and the full safety dataset before underwriting upside.

Key Decisions for Investors

• Do not chase a sharp headline-driven ALMS move. Treat the planned NDA filing as a catalyst to monitor, not an approval proxy; confirm actual filing and FDA acceptance before increasing exposure.
• For a bullish event position, consider a small, defined-risk ALMS call spread expiring after the expected regulatory milestone, sized to lose the full premium. Avoid selecting strikes until current option pricing, implied volatility, and the stock’s post-release move are checked.
• Track whether the eventual label and safety review support differentiation from Sotyktu, and whether payers favor an oral entrant versus established oral and injectable options. Weak access or no meaningful safety/efficacy differentiation would undermine the share-gain thesis.
• Falsifiers: a delayed or rejected filing, an FDA request that materially extends review, safety findings that narrow use, or later evidence of weak persistence or unfavorable payer access. Reassess if any emerge rather than extrapolating the extension data.